Article
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Breast cancer research : BCR - 1 Jan 2010
Abraham Jean E, Maranian Mel J, Driver Kristy E, Platte Radka, Kalmyrzaev Bolot, Baynes Caroline, Luccarini Craig, Shah Mitul, Ingle Susan, Greenberg David, Earl Helena M, Dunning Alison M, Pharoah Paul D P, Caldas Carlos
Abstract excerpt
INTRODUCTION: Tamoxifen is one of the most effective adjuvant breast cancer therapies available. Its metabolism involves the phase I enzyme, cytochrome P4502D6 (CYP2D6), encoded by the highly polymorphic CYP2D6 gene. CYP2D6 variants resulting in poor metabolism of tamoxifen are hypothesised to reduce its efficacy. An FDA-approved pre-treatment CYP2D6 gene testing assay is available. However, evidence from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.